Avenue Therapeutics Statistics
Share Statistics
Avenue Therapeutics has 2.05M shares outstanding. The number of shares has increased by -89.2% in one year.
| Shares Outstanding | 2.05M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 52.11% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.84M |
| Failed to Deliver (FTD) Shares | 1.23K |
| FTD / Avg. Volume | 2.74% |
Short Selling Information
The latest short interest is 50.92K, so 2.66% of the outstanding shares have been sold short.
| Short Interest | 50.92K |
| Short % of Shares Out | 2.66% |
| Short % of Float | 2.8% |
| Short Ratio (days to cover) | 0.73 |
Valuation Ratios
The PE ratio is -0.16 and the forward PE ratio is -0.65.
| PE Ratio | -0.16 |
| Forward PE | -0.65 |
| PS Ratio | 0 |
| Forward PS | 0 |
| PB Ratio | 1.08 |
| P/FCF Ratio | -0.14 |
| PEG Ratio | n/a |
Enterprise Valuation
Avenue Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 1.55, with a Debt / Equity ratio of 0.
| Current Ratio | 1.55 |
| Quick Ratio | 1.55 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -6.56% and return on capital (ROIC) is -2223.24%.
| Return on Equity (ROE) | -6.56% |
| Return on Assets (ROA) | -5.61% |
| Return on Capital (ROIC) | -2223.24% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -3.46M |
| Employee Count | 3 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -83.96% in the last 52 weeks. The beta is -0.18, so Avenue Therapeutics 's price volatility has been lower than the market average.
| Beta | -0.18 |
| 52-Week Price Change | -83.96% |
| 50-Day Moving Average | 2.05 |
| 200-Day Moving Average | 4.51 |
| Relative Strength Index (RSI) | 37.94 |
| Average Volume (20 Days) | 44.84K |
Income Statement
In the last 12 months, Avenue Therapeutics had revenue of $0 and earned -$10.38M in profits. Earnings per share was $-73.6.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -14.54M |
| Net Income | -10.38M |
| EBITDA | 4.05M |
| EBIT | - |
| Earnings Per Share (EPS) | -73.6 |
Balance Sheet
The company has $1.78M in cash and $0 in debt, giving a net cash position of $1.78M.
| Cash & Cash Equivalents | 1.78M |
| Total Debt | 0 |
| Net Cash | 1.78M |
| Retained Earnings | -90.93M |
| Total Assets | 2.63M |
| Working Capital | 1.65M |
Cash Flow
In the last 12 months, operating cash flow was -$9.45M and capital expenditures -$3.00M, giving a free cash flow of -$12.45M.
| Operating Cash Flow | -9.45M |
| Capital Expenditures | -3.00M |
| Free Cash Flow | -12.45M |
| FCF Per Share | -88.3 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
ATXI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -4134.83% |
| FCF Yield | -340.57% |
Analyst Forecast
The average price target for ATXI is $56.25, which is 3060.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $56.25 |
| Price Target Difference | 3060.1% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Apr 26, 2024. It was a backward split with a ratio of 1:75.
| Last Split Date | Apr 26, 2024 |
| Split Type | backward |
| Split Ratio | 1:75 |
Scores
| Altman Z-Score | -62.18 |
| Piotroski F-Score | 3 |